AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10792556
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - transdermal application of continuous 17-beta oestradiol with cyclic medroxyprogesterone acetate tablets every 3rd month for 14 days
Trial: 10792556
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - sequential administration of medroxyprogesterone acetate
Trial: 10792556
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - during medroxyprogesterone administration
Trial: 9065187
Drug: Gestrinone 2.5
RxNorm normalized name: gestrinone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone 2.5 mg
Trial: 9065187
Drug: Gestrinone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone 1.25 mg
Trial: 27449527
Drug: G + MH intervention
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: G + MH intervention (mental health Internet interventions + gambling intervention)
Trial: 27449527
Drug: G‐only intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐only intervention (gambling intervention only)
Trial: 24231016
Drug: Test food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test food containing 300 mg calcium, 150 mg magnesium, and 4.0 g lactulose
Trial: 19016185
Drug: Jinniu capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinniu capsules
Trial: 11111143
Drug: Slow-release twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slow-release twice-daily nifedipine
Trial: 11111143
Drug: Nifedipine (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (without specifying dosage or duration)
Trial: 24995890
Drug: Adjunctive edivoxetine
RxNorm normalized name: Edivoxetine
DrugBank: Edivoxetine (DB09184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive edivoxetine (6-18 mg once daily)
Trial: 21050498
Drug: Carbon ion
RxNorm normalized name: CARBON ION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon ion radiation therapy (60 Gy E ± 5%)
Trial: 21050498
Drug: Proton radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton radiation therapy (70 Gy E ± 5%)
Trial: 21050498
Drug: Carbon ion
RxNorm normalized name: CARBON ION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon ion radiation therapy
Trial: 21050498
Drug: Proton radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton radiation therapy
Trial: 9083709
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (immediately before each meal)
Trial: 9083709
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin (30 to 45 minutes before eating)
Trial: 1976052
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg cimetidine
Trial: 3993320
Drug: Bupivacaine (22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (22.5 mg)
Trial: 3993320
Drug: Glucose-containing bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-containing bupivacaine (20 mg)
Trial: 3993320
Drug: Tetracaine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine (15 mg)
Trial: 30680521
Drug: Niraparib 300
RxNorm normalized name: niraparib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 300 mg once daily
Trial: 30129517
Drug: Supervised Structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised Structured Aerobic Exercise Training (SSAET) program, routine medication, and dietary plan for 25 weeks.
Trial: 30129517
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication and dietary plan for 25 weeks (Control group).
Trial: 25589316
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy including antibiotics, vessels extending drugs, neuroprotective and detoxification facilities.
Trial: 25589316
Drug: Cytoflavin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin 10 ml 0.9% NaCl 200 ml for 10 days, followed by 2 tablets 2 times a day orally for 1 month in addition to basic therapy.
Trial: 20837917
Drug: Intravenous T3
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous T3 as Triostat (n=98)
Trial: 19061712
Drug: Granulocyte-colony stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony stimulating factor (G-CSF) administered at 10 microg/kg SC for 5 days, followed by leukapheresis and randomized double-blinded intracoronary infusion of CD133+ or unselected cells after 3 months
Trial: 8651085
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (40 mg subcutaneously per day for 25 days, n=43)
Trial: 8651085
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment, n=60)
Trial: 1521210
Drug: Low-dose prednisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisone (263 patients)
Trial: 25967993
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment (HBOT)
Trial: 28983968
Drug: Individualized 6-mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized 6-mercaptopurine increments (stepwise increments of additional 25 mg/m2/day starting on days 50 and/or 71)
Trial: 28983968
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (oral 6-mercaptopurine 25 mg/m2/day from days 30 to 85)
Trial: 26937858
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (n = 62)
Trial: 24958315
Drug: Continuous intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intra-articular infusion anesthesia
Trial: 24958315
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion anesthesia
Trial: 21105289
Drug: Levetiracetam (LV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LV) administered in a fixed dose schedule over 6 days
Trial: 15696988
Drug: Intralesional injections
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injections of 2% zinc sulfate solution
Trial: 10591351
Drug: Corticosteroid (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (60 mg methylprednisolone IM and 12 mg dexamethasone IV)
Trial: 9088130
Drug: Doxazosin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin therapy (Group 3, n = 64)
Trial: 1651859
Drug: Terbutaline 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 1.25 mg
Trial: 29340854
Drug: 12 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 sessions of fractionated thulium laser treatment
Trial: 29340854
Drug: Post-laser treatment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-laser treatment application of growth factor (GF) solution
Trial: 22323303
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure therapy
Trial: 26926656
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure therapy (adherent group)
Trial: 25340832
Drug: Ozenoxacin 1%
RxNorm normalized name: OZENOXACIN 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozenoxacin 1% cream
Trial: 25209521
Drug: Ozenoxacin 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozenoxacin 2% cream
Trial: 12678340
Drug: NaP (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaP (oral sodium phosphate)
Trial: 12678340
Drug: PEG (polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG (polyethylene glycol electrolyte lavage solution)
Trial: 10740542
Drug: Dopexamine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine 1.0 mg kg‐1 over 5 min, followed by an infusion of 2 micrograms kg‐1 min‐1
Trial: 1430505
Drug: Dentifrices containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrices containing 15 mg percent xylitol
Trial: 3972929
Drug: Hypnotherapy (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnotherapy (6 standardized sessions, one hourly session per week)
Trial: 31855909
Drug: 12-week single-legged
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week single-legged decline-squat exercise + weekly session of ESWT for 6 weeks
Trial: 29940797
Drug: Tele-delivered mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-delivered mindfulness-based cognitive therapy
Trial: 23877988
Drug: Sitagliptin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin alone or in combination with glargine insulin
Trial: 23877988
Drug: Basal bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal bolus insulin regimen (glargine and lispro) plus supplemental doses of lispro
Trial: 20108652
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Bellissima)
Trial: 16426094
Drug: Lithium (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (serum concentration 0.6 to 1.2 mEq/L)
Trial: 15450048
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (OS) for 3 months
Trial: 31853103
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 0.5mg/kg in 5ml
Trial: 28013123
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin 40 IU taken four times a day (QID)
Trial: 26174460
Drug: Avena sativa
RxNorm normalized name: Avena Sativa
DrugBank: Avena sativa flowering top (DB14253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avena sativa lotion, twice a day for 2 weeks
Trial: 26174460
Drug: Hydroxyzine tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine tablets, for 2 weeks
Trial: 12964648
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group received antimicrobial treatment (topical application of NaF and iodine solution) and restorative care using glass ionomer cement.
Trial: 12964648
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received primary care intervention and oral hygiene kits.
Trial: 12964648
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received primary care intervention and oral hygiene kits.
Trial: 11518470
Drug: Fibrin-glue coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin-glue coated collagen patch
Trial: 9401830
Drug: Carbamazepine 400
RxNorm normalized name: carbamazepine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 400 mg retard AWD (test)
Trial: 22734586
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) at a fixed dose of 10 mg/kg/day for 18 months
Trial: 20371785
Drug: Methotrexate therapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate therapy for 6 months (group 1, n = 183)
Trial: 20371785
Drug: Methotrexate therapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate therapy for 12 months (group 2, n = 181)
Trial: 20371785
Drug: Methotrexate therapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate therapy for 6 months (group 1)
Trial: 20371785
Drug: Methotrexate therapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate therapy for 12 months (group 2)
Trial: 17325227
Drug: Fosmidomycin‐clindamycin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmidomycin‐clindamycin therapy given every 12 h for 3 days
Trial: 17325227
Drug: Sulfadoxine‐pyrimethamine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine‐pyrimethamine (single oral dose)
Trial: 9539595
Drug: Selective group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective group (R and MC nerves blocked with 10 mL of 2% lidocaine each; M and U nerves blocked with 10 mL of 0.5% bupivacaine each)
Trial: 9539595
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (each of the four nerves infiltrated with 10 mL of a mixture of 2% lidocaine and 0.5% bupivacaine)
Trial: 8091142
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg bid
Trial: 20510987
Drug: Usual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual therapy only (Control)
Trial: 30945504
Drug: Internal heat-type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal heat-type acupuncture needle therapy (IHTAN), 42 ℃, 20 min, once a week for 4 weeks
Trial: 30945504
Drug: Warm needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needle moxibustion therapy, once every other day for 4 weeks
Trial: 28917230
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg green coffee bean extract for 8 weeks
Trial: 1673495
Drug: ICI 204,219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 204,219 (40 mg by mouth)
Trial: 7047329
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intrathecal immunoglobulin (Ig) therapy: 10 g Ig as a short infusion on two consecutive days, plus 500 mg by intrathecal injection every second day for bacterial infections and every fifth day for viral infections.
Trial: 7047329
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received usual therapy only, principally antibiotics for purulent meningitis.
Trial: 24622414
Drug: Alefacept (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept (15 mg intramuscularly per week for two 12-week courses, separated by a 12-week pause)
Trial: 18813407
Drug: Ketamine 1
RxNorm normalized name: ketamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 1 mg/kg (group K)
Trial: 18813407
Drug: Pethidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 0.5 mg/kg (group P)
Trial: 12781852
Drug: 400 microg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg/d folic acid supplement
Trial: 10692621
Drug: Systemic lidocaine
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic lidocaine (2 mg/kg bolus followed by 2 mg kg(‐1)h(‐1) infusion)
Trial: 10692621
Drug: Regional lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional lidocaine (40 ml lidocaine, 0.05%)
Trial: 10692621
Drug: Control (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (40 ml NaCl, 0.9%)
Trial: 9459116
Drug: Intravenous polyvalent
RxNorm normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous polyvalent immunoglobulins (IVIG) at a dose of 1 g/kg for 3 days
Trial: 1585493
Drug: Both EC
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both EC and UW solutions
Trial: 26509765
Drug: i‐gel (laryngeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i‐gel (laryngeal mask)
Trial: 24622832
Drug: Tryptophan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan (2 x 500 mg/day) and Essentiale forte (3 x 1 tablet/day) for 14 months
Trial: 24622832
Drug: Melatonin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (2 x 5 mg/day) and Essentiale forte (3 x 1 tablet/day) for 14 months
Trial: 20435245
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of tramadol 100 mg
Trial: 20435245
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of tramadol 100 mg
Trial: 19014839
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of lamotrigine (100 mg)
Trial: 19014839
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of lamotrigine (100 mg)
Trial: 14675880
Drug: Bisoprolol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 1.25 mg (increased to a maximum dose of 5 mg per day)
Trial: 14675880
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard therapy with diuretic and ACE inhibitor)
Trial: 12434619
Drug: 15% in-office
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% in-office hydrogen peroxide tooth-whitening touch-up agent
Trial: 1828225
Drug: Monophasic combined
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic combined oral contraceptive (130 micrograms ethinylestradiol + 150 micrograms desorgestrel)
Trial: 1828225
Drug: Triphasic combined
RxNorm normalized name: Tribasic Calcium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic combined oral contraceptive (30 micrograms ethinylestradiol + 50 micrograms levonorgestrel for 6 days, followed by 40 micrograms ethinylestradiol + 75 micrograms levonorgestrel for 5 days and 30 micrograms ethinylestradiol + 125 micrograms levonorgestrel for 10 days)
Trial: 6123122
Drug: 5 or
RxNorm normalized name: Acys-5 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or 10 mg mepindolol
Trial: 6123122
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg mepindolol
Trial: 31292969
Drug: High-dose tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tablets (LF 60 mg/d, LPO 7.8 mg/d)
Trial: 31292969
Drug: Low-dose tablets
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tablets (LF 20 mg/d, LPO 2.6 mg/d)
Trial: 19150955
Drug: First-line combination
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line combination therapy with capecitabine and irinotecan (specific dosage and duration not mentioned)
Trial: 15076791
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (200 mg.wk(‐1), intramuscularly)
Trial: 9847429
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous nasal spray, 256 microgram
Trial: 9847429
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous suspension, 200 microgram
Trial: 8021907
Drug: Propranolol (40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40-120 mg)
Trial: 8021907
Drug: Verapamil (80-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80-200 mg)
Trial: 2640054
Drug: FDP 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDP 20 g
Trial: 811471
Drug: 30 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mug TRH (single injection)
Trial: 811471
Drug: 30 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mug TRH (six injections with 30 minutes interval)
Trial: 29665158
Drug: Gastrointestinal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrointestinal delivery oral immunotherapy (GIDOIT) with peanut capsules, 2 to 400 mg of peanut protein daily for 24 weeks